Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

Compre a edição $396.00 Volume 21, 2001 Edição 1-3

DOI: 10.1615/CritRevImmunol.v21.i1-3

Sumário:

A Nondeletional Mechanism for Central T-Cell Tolerance
Robert L. Rubin, Anke Kretz-Rommel
12 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.20
T-Cell Receptor-Derived Peptides in Immunoregulation and Therapy of Retrovirally Induced Immunosuppression
John J. Marchalonis, Ian F. Robey, Allen B. Edmundson, R. Tomas Sepulveda, Ronald R. Watson
18 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.40
Induction and Direction of Immune Responses by Vaccine Adjuvants
Virgil E. J. C. Schijns
11 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.50
The Basis of Immunogenicity of Endocrine Allografts
Mark R. Nicolls, Marilyne Coulombe, Ronald G. Gill
15 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.60
The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants
Risini D. Weeratna, Paul J. Payette, Heather L. Davis
18 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.70
Peripheral Nonresponsiveness to Orally Administered Soluble Protein Antigens
Cathryn Nagler-Anderson, Hai Ning Shi
11 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.80
Dendritic Cells in Cancer Immunotherapy
Matthias Gunzer, Stephan Grabbe
13 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.90
Therapeutic Potential of Leukemia-Derived Dendritic Cells: Preclinical and Clinical Progress
David F. Claxton, John McMannis, Richard E. Champlin, Aniruddha Choudhury
9 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.100
Diverse Functional Activity of CD83+ Monocyte-Derived Dendritic Cells and the Implications for Cancer Vaccines
Brian J. Czerniecki, Peter A. Cohen, Mark B. Faries, Shuwen Xu, James G. Roros, Isabelle Bedrosian
22 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.110
CD14+ Monocytes as Dendritic Cell Precursors: Diverse Maturation-Inducing Pathways Lead to Common Activation of NF-kB/RelB
Gary K. Koski, Lyudmila A. Lyakh, Peter A. Cohen, Nancy R. Rice
12 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.120
The Identification and Development of Specific Monoclonal Antibodies to Squamous Cell Carcinoma
Myron Arlen, Al Tsang, Joseph Scherrer, Joyce Wolf, Olga Saric
10 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.140
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Liaomin Peng, Peter A. Cohen, Jorgen Kjaergaard, Gregory E. Plautz, James H. Finke, Gary K. Koski, Brian J. Czerniecki, Suyu Shu
34 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.150
A Unique Folate Hydrolase, Prostate-Specific Membrane Antigen (PSMA): A Target For Immunotherapy?
Jason Tasch, Mike Gong, Michel Sadelain, Warren D. W. Heston
13 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.160
Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model
Mary L. Disis, Keith L. Knutson, Douglas G. McNeel, Donna Davis, Kathy Schiffman
11 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.170
Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines
Amy C. Hobeika, Timothy M. Clay, Paul J. Mosca, H. Kim Lyerly, Michael A. Morse
11 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.190
Overexpressed Cell Surface Interleukin-4 Receptor Molecules Can Be Successfully Targeted for Antitumor Cytotoxin Therapy
Koji Kawakami, Mariko Kawakami, Raj K. Puri
12 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.200

Critical Reviews™ in Immunology

Model for the recruitment of inducer-specific TNF-α gene enhanceosome in T lymphocytes., Vol. 29, Iss.2, Viral Mechanisms Involved in the TranscriptionalCBP/p300 Regulation of Inflammat..... Model for the recruitment of inducer-specific TNF-α gene enhanceosome in T lymphocytes., Vol. 29, Iss.2, Viral Mechanisms Involved in the TranscriptionalCBP/p300 Regulation of Inflammat..... Viral Mechanisms Involved in the Transcriptional CBP/р300 Regulation of Inflammatory and Immune Responses
Activation of several B cells is necessary for exosome release.Vol. 29, Iss. 3, Exosome Release by Primary B Cells. Activation of several B cells is necessary for exosome release.Vol. 29, Iss. 3, Exosome Release by Primary B Cells. Exosome Release by Primary B Cells
Homology model of human GrM. Vol. 29, Iss. 4, The Biology of Granzyme M: A Serine Protease with Unique Features. Homology model of human GrM. Vol. 29, Iss. 4, The Biology of Granzyme M: A Serine Protease with Unique Features. Biology of Granzyme M: A Serine Protease with Unique Features
(A) Gap-junction formation, (B) A three-dimensional collagen matrix Vol. 30, Iss. 6, Endothelial Cells as Key Determinants of the Tumor Microenvironment. (A) Gap-junction formation, (B) A three-dimensional collagen matrix Vol. 30, Iss. 6, Endothelial Cells as Key Determinants of the Tumor Microenvironment. Endothelial Cells as Key Determinants of the Tumor Microenvironment: Interaction with Tumor Cells, Extracellular Matrix and Immune Killer Cells
Biphasic HCV RNA decline after IFN treatment of chronic hepatitis C. Vol. 30, Iss. 2, Treatment of Hepatitis C Virus Infection with Interferon and Small Molecule Direct Antivirals. Biphasic HCV RNA decline after IFN treatment of chronic hepatitis C. Vol. 30,  Iss. 2, Treatment of Hepatitis C Virus Infection with Interferon and Small Molecule Direct Antivirals. Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling